Advertisement
GMAB vs NVO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMAB is a Buy and NVO is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GMAB’s FA Score shows that 0 FA rating(s) are green whileNVO’s FA Score has 2 green FA rating(s).
- GMAB’s FA Score: 0 green, 5 red.
- NVO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GMAB’s TA Score shows that 5 TA indicator(s) are bullish while NVO’s TA Score has 4 bullish TA indicator(s).
- GMAB’s TA Score: 5 bullish, 4 bearish.
- NVO’s TA Score: 4 bullish, 3 bearish.
Price Growth
GMAB (@Biotechnology) experienced а +9.04% price change this week, while NVO (@Pharmaceuticals: Major) price change was +0.05% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.44%. For the same industry, the average monthly price growth was +9.90%, and the average quarterly price growth was +31.78%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.01%. For the same industry, the average monthly price growth was +3.85%, and the average quarterly price growth was +10.24%.
Reported Earning Dates
GMAB is expected to report earnings on Nov 06, 2025.
NVO is expected to report earnings on Nov 05, 2025.
Industries' Descriptions
@Biotechnology (+2.44% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (+1.01% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| GMAB | NVO | GMAB / NVO | |
| Capitalization | 16.7B | 253B | 7% |
| EBITDA | 1.48B | 154B | 1% |
| Gain YTD | 31.193 | -32.937 | -95% |
| P/E Ratio | 14.16 | 14.44 | 98% |
| Revenue | 3.26B | 312B | 1% |
| Total Cash | 2.9B | N/A | - |
| Total Debt | 148M | N/A | - |
GMAB | NVO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 26 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 58 Fair valued | 16 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 78 | |
SMR RATING 1..100 | 37 | 15 | |
PRICE GROWTH RATING 1..100 | 43 | 64 | |
P/E GROWTH RATING 1..100 | 89 | 98 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVO's Valuation (16) in the Pharmaceuticals Major industry is somewhat better than the same rating for GMAB (58) in the null industry. This means that NVO’s stock grew somewhat faster than GMAB’s over the last 12 months.
NVO's Profit vs Risk Rating (78) in the Pharmaceuticals Major industry is in the same range as GMAB (100) in the null industry. This means that NVO’s stock grew similarly to GMAB’s over the last 12 months.
NVO's SMR Rating (15) in the Pharmaceuticals Major industry is in the same range as GMAB (37) in the null industry. This means that NVO’s stock grew similarly to GMAB’s over the last 12 months.
GMAB's Price Growth Rating (43) in the null industry is in the same range as NVO (64) in the Pharmaceuticals Major industry. This means that GMAB’s stock grew similarly to NVO’s over the last 12 months.
GMAB's P/E Growth Rating (89) in the null industry is in the same range as NVO (98) in the Pharmaceuticals Major industry. This means that GMAB’s stock grew similarly to NVO’s over the last 12 months.
| GMAB | NVO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 63% | 2 days ago 68% |
| Stochastic ODDS (%) | 2 days ago 62% | 2 days ago 58% |
| Momentum ODDS (%) | 2 days ago 57% | 2 days ago 76% |
| MACD ODDS (%) | 2 days ago 60% | 2 days ago 81% |
| TrendWeek ODDS (%) | 2 days ago 61% | 2 days ago 62% |
| TrendMonth ODDS (%) | 2 days ago 63% | 2 days ago 66% |
| Advances ODDS (%) | 2 days ago 63% | 15 days ago 67% |
| Declines ODDS (%) | 26 days ago 69% | 11 days ago 59% |
| BollingerBands ODDS (%) | 2 days ago 64% | 2 days ago 51% |
| Aroon ODDS (%) | 2 days ago 48% | N/A |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JULZ | 45.23 | 0.49 | +1.09% |
| Trueshares Structured Outcome July ETF | |||
| QQQT | 17.87 | 0.17 | +0.96% |
| Defiance Nasdaq 100 Income Target ETF | |||
| DEUS | 58.09 | 0.49 | +0.85% |
| Xtrackers Russell US Multifactor ETF | |||
| NIE | 24.96 | 0.21 | +0.85% |
| Virtus Equity & Convertible Income Fund | |||
| SLV | 36.93 | -0.41 | -1.10% |
| iShares Silver Trust | |||
GMAB and
Correlation & Price change
A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with GNMSF. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then GNMSF could also see price increases.
| Ticker / NAME | Correlation To GMAB | 1D Price Change % | ||
|---|---|---|---|---|
| GMAB | 100% | +1.11% | ||
| GNMSF - GMAB | 58% Loosely correlated | N/A | ||
| AXON - GMAB | 47% Loosely correlated | +0.67% | ||
| TECH - GMAB | 38% Loosely correlated | -0.79% | ||
| ARVN - GMAB | 37% Loosely correlated | -3.67% | ||
| IPSC - GMAB | 36% Loosely correlated | +2.26% | ||
More | ||||
NVO and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVO has been closely correlated with NONOF. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVO jumps, then NONOF could also see price increases.
| Ticker / NAME | Correlation To NVO | 1D Price Change % | ||
|---|---|---|---|---|
| NVO | 100% | -1.06% | ||
| NONOF - NVO | 70% Closely correlated | -1.33% | ||
| TECH - NVO | 36% Loosely correlated | -0.79% | ||
| GMAB - NVO | 35% Loosely correlated | +1.11% | ||
| BCAB - NVO | 33% Loosely correlated | +2.13% | ||
| MRK - NVO | 32% Poorly correlated | -0.15% | ||
More | ||||